Adult Dosing
Mild to moderate Alzheimer's dementia
Immediate release
- Start 4 mg PO bid; can increase by 4 mg bid q4 wks up to 12 mg bid as tolerated
- Max: 24 mg/day
Extended release
- Start 8 mg PO qam; can increase by 8 mg/day q4 wks up to 24 mg/day as tolerated
- Max: 24 mg/day
Pediatric Dosing
- Safety and effectiveness in pediatric patients has not been established
[Outline]
Renal Dose Adjustment (Based on CrCl)
- Moderate impairment: Max 16 mg/day PO
- Severe impairment ( <9 mL/min): Not recommended
Hepatic Dose Adjustment
- Moderate impairment (Child Pughs 7-9): Max 16 mg/day PO
- Severe impairment (Child Pughs 10-15): Not recommended
See Supplemental Patient Information
- Exaggerates the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blockers during anesthesia
- Bradycardia and AV block have occurred due to vagotonic effects on the sinoatrial and atrioventricular nodes. Bradycardia and all types of heart block have been reported in patients with and without known underlying cardiac conduction abnormalities on post-marketing surveillance; consider all patients at risk for adverse effects on cardiac conduction. Dose related increase at risk of syncope have occurred in patients treated with galantamine up to 24 mg/day using the recommended dosing regimen
- Closely monitor patients for symptoms of active or occult GI bleeding, especially those having an increased risk for developing ulcers
- Cholinomimetics may induce bladder outflow obstruction
- Exhibits potential to induce generalized convulsions
- Prescribe with care to patients having a history of severe asthma or obstructive pulmonary disease
- Monitor Cr at baseline
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- Asthma
- COPD
- Cardiac conduction disorders
- History of peptic ulcer disease
- History of GI bleed
- Seizure disorder
- Urinary tract obstruction
- Anaesthesia/surgery
- Concomitant NSAIDs use
Supplemental Patient Information
- Instruct caregivers about the recommended dosage and administration of this drug
- Advise patients and caregivers that the most frequent adverse events associated with this therapy can be minimized by following the recommended dosage and administration
- Advise patients to ensure adequate fluid intake during therapy
Pregnancy Category:B
Breastfeeding: Safety unknown. Has no indication for use in nursing mothers.
Pricing data from www.DrugStore.com in U.S.A.
- Razadyne 4 MG TABS [Bottle] (JANSSEN)
30 mg = $109.99
90 mg = $329.96 - Razadyne ER 8 MG CP24 [Bottle] (JANSSEN)
30 mg = $225.98
90 mg = $629.96 - Razadyne 12 MG TABS [Bottle] (JANSSEN)
30 mg = $112.16
90 mg = $314.05 - Razadyne 8 MG TABS [Bottle] (JANSSEN)
30 mg = $112.16
90 mg = $314.05 - Razadyne ER 24 MG CP24 [Bottle] (JANSSEN)
30 mg = $225.98
90 mg = $625.99 - Razadyne ER 16 MG CP24 [Bottle] (JANSSEN)
30 mg = $225.98
90 mg = $629.96
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
